Response

Multilayered Control of T Cell Receptor Phosphorylation
We would like to respond to the Correspondence by Fernandes et al., but first we will summarize the data in our Cell paper . Our study used a biophysical approach to examine the binding of the CD33 cytoplasmic domain (CD33CD) to the plasma membrane. We reported a new FRET assay to examine CD33CD binding to the inner leaflet of the plasma membrane in live Jurkat cells, a transformed T cell line. Furthermore, we developed an approach to determine the NMR structure of CD33CD bound in a lipid bilayer environment. The structure showed that the two tyrosines of the immunoreceptor tyrosine-based activation motif (ITAM) partitioned into the hydrophobic core of the bilayer in a dynamic manner, with substantial movement of the two tyrosines and other elements of the cytoplasmic domain ( Figure 6 , . Microscopy data yielded similar FRET values for CD33CD tagged with C-terminal teal fluorescent protein (TFP) and for a positive control in which TFP was in close proximity to the plasma membrane (there was a three amino acid linker between the transmembrane and TFP domains). These data indicated that most of the cytoplasmic domain was membrane bound in these transfected nonstimulated Jurkat cells. However, we did not claim that all CD33 cytoplasmic domains in a given T cell are completely bound to the plasma membrane. This would be impossible in a biological system because binding events always follow equilibrium conditions, with the size of the bound versus free fractions being determined by the ratio of on and off rates. It follows that changes in equilibrium can result in dissociation of CD33CD from the membrane. Our data showed a structure with substantial mobility in which changes in equilibrium, such as recruitment of the tyrosine kinase Lck, could enable phosphorylation.
We wish to point out that we did not claim that binding of CD33CD to the membrane was the only mechanism that prevents spontaneous T cell signaling. It is well established that there is multilayered control of T cell receptor (TCR) signaling because complete phosphorylation of even one or a few TCRs is sufficient to result in T cell activation (Bergman et al., 1992; Davis and van der Merwe, 2006) . Without highly effective mechanisms to prevent spontaneous signaling, rampant chronic inflammation and autoimmunity would result. Spontaneous signaling is inhibited by the Csk kinase, which phosphorylates Lck kinase at inhibitory tyrosine 505, as well as multiple phosphatases (Bergman et al., 1992; Davis and van der Merwe, 2006) . In agreement with Fernandes et al., we did not detect phosphorylation of the CD33CD Emut1+2 mutant protein in Jurkat cells ( Figure S1B , CD33-Mut time 0), which was a negative control for the FRET experiments. However, if binding of CD33 to the membrane together with other inhibitory mechanisms guards against spontaneous phosphorylation, this result is not surprising. Phosphorylation may only be favored with appropriate TCR localization into microclusters that exclude the CD45 phosphatase (Varma et al., 2006) , as well as simultaneous colocalization of active Lck bound to CD4/CD8 coreceptors close to the clustered TCR-CD3 complexes.
Fernandes et al. assume that the CD33CD Emut1+2 mutant protein would normally interact with Lck. However, the loss of six basic residues substantially changes its charge properties. We therefore directly compared the phosphorylation of the mutant and wild-type CD33CD proteins in an in vitro phosphorylation assay with the purified cytoplasmic domains of the wild-type and Emut1+2 proteins and purified Lck in the absence of liposomes ( Figure S1A ). We observed greatly reduced phosphorylation of the mutant protein, even though equal amounts of wild-type and mutant proteins were used. The mutant protein was not detectably phosphorylated with 100 ng of Lck kinase and was only phosphorylated at low levels with 400 ng Lck; the wild-type protein was robustly phosphorylated under both conditions. Fernandes et al. also mention delayed phosphorylation kinetics for this mutant protein in cells treated with pervanadate, which inhibits a broad range of phosphatases (data not shown). We confirmed this finding and observed substantially delayed phosphorylation of the mutant protein after pervanadate treatment: the wild-type protein was phosphorylated after 2 min, whereas phosphorylation of the mutant was delayed, with a 3.5-to 5-fold reduction at 10 min ( Figure S1B ). However, both proteins were phosphorylated to a similar degree at a later time point (30 min), as Fernandes et al. also showed. The greatly reduced interaction of the mutant protein with Lck as well as the multiple control mechanisms regulating T cell activation could account for the absence of observable phosphorylation of this particular CD33 mutant in nonstimulated Jurkat cells. It is not known why mutation of six basic residues in the N-terminal part of CD33CD reduces the interaction with Lck, but conformational changes in the cytoplasmic domain or loss of long-range charge interactions with Lck could be involved.
Pervanadate oxidizes the active site cysteines of many different phosphatases and is generated by mixing hydrogen peroxide with sodium orthovanadate (Huyer et al., 1997) . Given the potential for unanticipated effects, we used our FRET assay to examine the consequences of pervanadate treatment on CD33CD membrane binding . The assay measures the interaction of a TFP domain attached to the C terminus of CD33CD with a lipophilic dye R18 (octadecyl rhodamine B) incorporated in the plasma membrane; labeling the cells with R18 caused a decrease in the TFP signal (quenching) due to energy transfer from TFP to R18 (Figure S1C ). In the absence of pervanadate, the FRET efficiency was high (average 50%; Figure S1D ), which is similar to the FRET signal obtained with the positive control in which TFP is positioned close to the plasma membrane (a three amino acid linker between the transmembrane domain and TFP) . After 20 min of pervanadate treatment, the FRET signal was reduced on average to 15% (Figure S1D ), similar to the negative control with a 50 amino acid flexible linker between the transmembrane domain and TFP . Pervanadate treatment thus results in dissociation of the CD33 cytoplasmic domain from the membrane.
We next examined the potential mechanisms that could contribute to this effect. We had previously shown that basic residues of CD33CD are critical for its binding to the plasma membrane. Therefore, we assessed whether the negative charge of the inner leaflet of the plasma membrane could be affected. Phosphatidylserine is the most abundant negatively charged lipid in the inner leaflet. We used a highly specific calcium-independent phosphatidylserine probe, the Lactadherin C2 domain (Lact-C2), to study the dynamics of phosphatidylserine distribution (Yeung et al., 2008) . Jurkat cells were transduced with a lentivirus containing the Lact-C2 probe, and the probe's localization in live cells was analyzed by confocal microscopy ( Figure S1E ). Under resting conditions, the Lact-C2 probe predominantly associated with the plasma membrane in 75% of cells. In contrast, pervanadate treatment reduced the Lact-C2 signal at the plasma membrane and increased the amount of this phosphatidylserine probe in internal membranes in 92% of cells, suggesting that the plasma membrane inner leaflet had a reduced negative charge ( Figures S1E and S1F) . Phosphatidylserine at the cell surface was also slightly increased, as measured by annexin-V labeling ( Figure S1G ). We conclude that pervanadate treatment reduces the negative charge of the inner leaflet and induces release of CD33CD from the plasma membrane. These findings complicate the interpretation of experiments using pervanadate to assess whether CD33CD is bound to the plasma membrane.
A recent study confirmed that CD33CD binds to the plasma membrane (DefordWatts et al., 2009) , and prior work has shown that CD3z is membrane bound (Aivazian and Stern, 2000) . Furthermore, other cytoplasmic peptides have been shown to interact with the inner leaflet by similar mechanisms. McLaughlin and colleagues showed that the MARCKS peptide binds to the inner leaflet using clusters of basic amino acids and five phenylalanine residues (Zhang et al., 2003) . NMR measurements demonstrated directly that these phenylalanine residues are located in the hydrophobic core of the lipid bilayer, similar to the tyrosines of CD33CD (Zhang et al., 2003) . Also, the cytoplasmic small GTPase Rit localizes to the plasma membrane using three clusters of basic amino acids and interspersed hydrophobic residues; mutation of a tryptophan in this segment results in loss of membrane binding (Heo et al., 2006) . Therefore, usage of both basic and hydrophobic residues for plasma membrane binding is a more general theme that extends beyond the CD33 and z cytoplasmic domains of the TCR-CD3 complex.
In their Correspondence, Fernandes et al. raise questions about the functional relevance of the binding of CD33CD to the plasma membrane during TCR activation. It will be important to further study the functional significance of the binding of CD33CD to the plasma membrane in a physiological setting using primary T cells because the early events in TCR triggering are very complex, and subtle changes may result in receptor activation after ligand binding. Analysis of multiple CD33CD mutant proteins will be useful, including mutants with reduced rather than complete loss of membrane binding. 
